ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4970ometendo-4970Research ArticleСтатьиArticlesНовые возможности в лечении и ведении акромегалииNew opportunities in the treatment and management of acromegalyDalantaevaN S

аспирант отделения нейроэндокринологии и остеопатий

nsdalantaeva@gmail.comPigarovaE A

к.м.н., ст.н.с. отделения нейроэндокринологии и остеопатий

kpigarova@gmail.comDzeranovaL K

д.м.н., гл.н.с. отделения нейроэндокринологии и остеопатий

metabol@endocrincentr.ruRozhinskayaL Ya

проф., д.м.н., зав. отделением нейроэндокринологии и остеопатий

-DedovI I

директор ФГБУ Эндокринологический научный центр Минздравсоцразвития

dedov@endocrincentr.ru20121509201293№3 (2012)2932Copyright © Dalantaeva N.S., Pigarova E.A., Dzeranova L.K., Rozhinskaya L.Y., Dedov I.I., 20122012Dalantaeva N.S., Pigarova E.A., Dzeranova L.K., Rozhinskaya L.Y., Dedov I.I.Dalantaeva N.S., Pigarova E.A., Dzeranova L.K., Rozhinskaya L.Y., Dedov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4970

Генетические аспекты семейных изолированных аденом гипофиза (FIPA) стремительно расширяются в течение последних нескольких лет. Обнаружено, что около 20% этих семей FIPA имеют мутации в гене AIP, кодирующем белок арилуглеводородного рецептора. Количество выявленных AIP-положительных FIPA семей растет во всем мире.

Genetic aspects of familial isolated pituitary adenomas (FIPA) are expanding rapidly in the last few years. Around 20% of these FIPA families have been identified to have mutations within the aryl hydrocarbon receptor interacting protein (AIP) gene. The number of identified AIP-positive FIPA families is increasing all over the world.

аденомы гипофизаAIPFIPApituitary adenomasReferencesAyuk J, Clayton RN, Holder G, et al. Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly. J Clin Endocrinol Metab. 2004;89(4):1613–17.Ayuk J, Clayton RN, Holder G, et al. Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly. J Clin Endocrinol Metab. 2004;89(4):1613–17.Herman-Bonert VS, Zib K, Scarlett JA, et al. Growth hormone receptor antagonist ther-apy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab. 2000;85:2958–61.Herman-Bonert VS, Zib K, Scarlett JA, et al. Growth hormone receptor antagonist ther-apy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab. 2000;85:2958–61.Trainer PJ, Drake WM, Katznelson L. et al. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171–1177.Trainer PJ, Drake WM, Katznelson L. et al. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171–1177.Jenkins P, Bates P, Carson MN, et al. Conventional Pituytary Irradiation Is Effective in Lower-ing Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly. J Clin Endocrinol Metab. 2006;91(4):1239–45.Jenkins P, Bates P, Carson MN, et al. Conventional Pituytary Irradiation Is Effective in Lower-ing Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly. J Clin Endocrinol Metab. 2006;91(4):1239–45.Parkinson C, Kassem M, Heickendorff L. et al. Pegvisomat-induced serum insulin-like growth factor-1 normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003;88:5650–5665.Parkinson C, Kassem M, Heickendorff L. et al. Pegvisomat-induced serum insulin-like growth factor-1 normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003;88:5650–5665.Camacho PM, Hossein G. Evidence-Based Endocrinology. 2nd edition. P 275–293.Camacho PM, Hossein G. Evidence-Based Endocrinology. 2nd edition. P 275–293.Korbonits M, Stiles CE. Chapter 11a1. Familial Isolated Pituitary Adenoma. Endotext.org.Korbonits M, Stiles CE. Chapter 11a1. Familial Isolated Pituitary Adenoma. Endotext.org.Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology. 2007;157:371–382.Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology. 2007;157:371–382.Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends in Endocrinology and Metabolism. 2010;21:419–427.Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends in Endocrinology and Metabolism. 2010;21:419–427.Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, et al. Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism. 2010;95:E373–E383.Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, et al. Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism. 2010;95:E373–E383.Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation. 2010;31:950–960.Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation. 2010;31:950–960.Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230.Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230.

The authors declare that there are no conflicts of interest present.